<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04671303</url>
  </required_header>
  <id_info>
    <org_study_id>ALTN-AFTN-II-01</org_study_id>
    <nct_id>NCT04671303</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy and Safety of Anlotinib Combined With Allitinib in Lung Cancer</brief_title>
  <official_title>This Study is To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule Combined With Allitinib Tablets in First-line Treatment of Advanced No-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Study is To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule Combined&#xD;
      with Allitinib Tablets in First-line Treatment of Advanced no-squamous and No-small Cell Lung&#xD;
      Cancer with Epidermal Growth Factor Receptor Mutation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Study is To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule Combined&#xD;
      with Allitinib Tablets in First-line Treatment of Advanced No-squamous and No-small Cell Lung&#xD;
      Cancer with Epidermal Growth Factor Receptor Mutation.&#xD;
&#xD;
      This study is a single arm, phase II study, including 18 to 36 subjects; Common Terminology&#xD;
      Criteria for Adverse Events 5.0 standard was used to evaluate adverse events of drugs, and&#xD;
      Response Evaluation Criteria In Solid Tumors 1.1 was used to evaluated efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Efficacy of drug therapy</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>The probability and severity of first cycle adverse events (AE) and serious adverse events (SAE) (based on Common Terminology Criteria for Adverse Events 5.0) and abnormal laboratory test indicators;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The overall efficacy was assessed by the investigators</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>Objective response rate (ORR) assessed by the investigators</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Anlotinib Hydrochloride Capsule Combined with Allitinib Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anlotinib Hydrochloride Capsule: Oral on an empty stomach, once a day, 1 capsule each time, orally for 2 consecutive weeks, stop for 1 week Allitinib Tablets：The dose of allitinib mesylate is 80 mg once a day, 2 tablets each time, taken orally on an empty stomach before breakfast.&#xD;
Take medicine continuously for 3 weeks (21 days) for 1 cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib Hydrochloride Capsule Combined with Allitinib Tablets</intervention_name>
    <description>Anlotinib Hydrochloride Capsule: Oral on an empty stomach, once a day, 1 capsule each time, orally for 2 consecutive weeks, stop for 1 week Allitinib Tablets：The dose of allitinib mesylate is 80 mg once a day, 2 tablets each time, taken orally on an empty stomach before breakfast.&#xD;
Take medicine continuously for 3 weeks (21 days) for 1 cycle.</description>
    <arm_group_label>Anlotinib Hydrochloride Capsule Combined with Allitinib Tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Locally advanced and/or metastatic NSCLC diagnosed histologically and/or&#xD;
             cytologically;&#xD;
&#xD;
          2. Age 18 and above; Eastern Cooperative Oncology Group Physical condition: 0~1; The&#xD;
             expected survival time is more than 3 months;&#xD;
&#xD;
          3. Patients must present with a previously reported exon deletion mutation of Epidermal&#xD;
             Growth Factor Receptor 19 .&#xD;
&#xD;
             The investigator confirmed that the report could reflect the patient's current genetic&#xD;
             status.&#xD;
&#xD;
          4. There is at least one measurable lesion other than brain lesion defined by Response&#xD;
             Evaluation Criteria In Solid Tumors 1.1 standard;&#xD;
&#xD;
          5. The main organs are functioning well,Adequate laboratory indicators.&#xD;
&#xD;
          6. Women of childbearing age should agree to use contraceptives during the study period&#xD;
             and for a period of six months after the study; Negative serum or urine pregnancy test&#xD;
             within 7 days prior to study inclusion, and must be non-lactating; Male patients&#xD;
             should agree to use contraception during the study period and for six months after the&#xD;
             end of the study period;&#xD;
&#xD;
          7. Patients voluntarily participated in this study, signed informed consent, and had good&#xD;
             compliance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior history of targeted Epidermal Growth Factor Receptor therapy and anti-angiogenic&#xD;
             drugs&#xD;
&#xD;
          2. Received chemical or biological drugs after the diagnosis of advanced stage;&#xD;
&#xD;
          3. Subjects had undergone surgery , radiation therapy or other anticancer therapies&#xD;
             within 4 weeks prior to the commencement of study treatment; Subjects who have&#xD;
             previously received local radiation therapy may be enrolled if the following&#xD;
             conditions are met: more than 4 weeks after the end of radiation therapy ;&#xD;
&#xD;
          4. Within 2 weeks before the start of the study, patients were treated with Chinese&#xD;
             medicines&#xD;
&#xD;
          5. Imaging shows that the tumor has invaded the periphery of important blood vessels or&#xD;
             the investigator has determined that the tumor is very likely to invade important&#xD;
             blood vessels and cause fatal bleeding during the follow-up study.&#xD;
&#xD;
          6. Uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated&#xD;
             drainage ;&#xD;
&#xD;
          7. Brain metastases with symptoms or symptom control time less than 2 weeks;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuankai S, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences and Peking Union Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuankai S, Doctor</last_name>
    <phone>010-87788268</phone>
    <email>medart@126.com</email>
  </overall_contact>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>December 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Shi Yuankai</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

